Our findings suggest that tuft cell-like SCLCs with strong BCL2 expression might be particularly suitable for PARP/BCL2 co-inhibition, which may provide a rationale for applying this strategy to NSCLCs, especially LCNEC. This evidence concerns the gene PARP1 and large cell neuroendocrine carcinoma.